Stock Price & Analysis

Sell ITCI as the stock is trading near Johnson & Johnson's acquisition price of $132, with limited upside potential. Hold or sell to avoid risks associated with the acquisition process.

The price prediction for ITCI stock in 2025 is expected to be around $132. This forecast aligns with the recent analyst price targets and the pending acquisition by Johnson & Johnson at $132 per share.

The S1 support level for ITCI Stock is $131.19 ,The R1 resistant level for ITCI Stock is $131.36.

As of the end of day on 2025-03-14, the price of ITCI Stock was $131.26.

The target price for ITCI Stock according to analyst rating is 130.83, with the highest price target at 132.00 and the lowest at 118.00. Analysts have a Moderate Buy rating on ITCI Stock overall.

The market cap of ITCI is $14.0B.

Analysis and Insights

Valuation Metrics

ITCI's valuation metrics suggest potential overvaluation. The stock currently trades at a high EV/EBITDA ratio of 11.92x and a price-to-sales (P/S) ratio of 6.32x, which are elevated compared to industry averages. Additionally, the price-to-book (P/B) ratio of 7.73x indicates a significant premium to book value.

Financial Performance

While ITCI has shown revenue growth in 2024, with quarterly revenues increasing from $144.87M to $199.23M, the company has consistently reported negative net income, ranging from -$15.25M to -$26.32M over the same period. This raises concerns about profitability despite top-line growth.

Analyst Sentiment

Recent analyst downgrades and price target adjustments suggest cautious sentiment. For example, Mizuho downgraded ITCI to Neutral with a $132 price target, aligning with Johnson & Johnson's acquisition price. This indicates limited upside potential.

Acquisition Impact

The pending acquisition by Johnson & Johnson at $132 per share has likely driven the stock price to its current level. However, with no competing bids expected, the stock may lack catalysts for further appreciation.

Conclusion

ITCI appears overvalued given its high valuation multiples, lack of profitability, and limited upside potential following the acquisition announcement. Investors should exercise caution.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

The predicted price for ITCI stock in 2030 is $140. This forecast considers the recent acquisition by Johnson & Johnson at $132 per share, setting a floor, and potential market growth.

ITCI has a total of 610 employees.